CN115232030A - Aryl urea compound and preparation method and pharmaceutical application thereof - Google Patents
Aryl urea compound and preparation method and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN115232030A CN115232030A CN202110441682.XA CN202110441682A CN115232030A CN 115232030 A CN115232030 A CN 115232030A CN 202110441682 A CN202110441682 A CN 202110441682A CN 115232030 A CN115232030 A CN 115232030A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- dmso
- nmr
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- -1 Aryl urea compound Chemical class 0.000 title description 23
- 239000004202 carbamide Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims abstract description 20
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000001308 synthesis method Methods 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000013078 crystal Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 54
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 9
- 108091007914 CDKs Proteins 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 229940126142 compound 16 Drugs 0.000 description 9
- CYFCVGAYSILWBF-UHFFFAOYSA-N N=C=O.ClC1=CC=CC=C1Cl Chemical compound N=C=O.ClC1=CC=CC=C1Cl CYFCVGAYSILWBF-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 4
- LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 4
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 4
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 4
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 4
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 4
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 4
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 3
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 3
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 3
- 108700012928 MAPK14 Proteins 0.000 description 3
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 3
- VKMHCUNVMPYMEE-UHFFFAOYSA-N N-[4-(2-aminoethyl)phenyl]pyridine-4-carboxamide Chemical compound C1=CC(CCN)=CC=C1NC(=O)C1=CC=NC=C1 VKMHCUNVMPYMEE-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005918 in vitro anti-tumor Effects 0.000 description 3
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IOXOZOPLBFXYLM-UHFFFAOYSA-N 2-(4-nitrophenyl)ethanamine Chemical compound NCCC1=CC=C([N+]([O-])=O)C=C1 IOXOZOPLBFXYLM-UHFFFAOYSA-N 0.000 description 2
- HMFOBPNVAAAACP-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound NCCC1=CC=C(C(F)(F)F)C=C1 HMFOBPNVAAAACP-UHFFFAOYSA-N 0.000 description 2
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- 101000910347 Arabidopsis thaliana CDPK-related kinase 3 Proteins 0.000 description 2
- 108010067499 Clk dual-specificity kinases Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000002428 Cyclin C Human genes 0.000 description 2
- 108010068155 Cyclin C Proteins 0.000 description 2
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 108010000837 Janus Kinase 1 Proteins 0.000 description 2
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 108700027650 Mitogen-Activated Protein Kinase 7 Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108010050276 Protein Kinase C-alpha Proteins 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004979 fampridine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VAYMIYBJLRRIFR-UHFFFAOYSA-N 2-tolyl isocyanate Chemical compound CC1=CC=CC=C1N=C=O VAYMIYBJLRRIFR-UHFFFAOYSA-N 0.000 description 1
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 1
- VNADJTWHOAMTLY-UHFFFAOYSA-N 4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinazoline-6-carbonitrile Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=C(CCNC=2C3=CC(=CC=C3N=CN=2)C#N)C=C2)C2=C1 VNADJTWHOAMTLY-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VKJXAQYPOTYDLO-UHFFFAOYSA-N 4-methylphenethylamine Chemical compound CC1=CC=C(CCN)C=C1 VKJXAQYPOTYDLO-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- HBDZYKBNSGMSNN-UHFFFAOYSA-N Cl.C(C)N.[N+](=O)([O-])C1=CC=CC=C1 Chemical compound Cl.C(C)N.[N+](=O)([O-])C1=CC=CC=C1 HBDZYKBNSGMSNN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 101710146524 Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000018691 Focal Adhesion Kinase 1 Human genes 0.000 description 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 108010080991 Mediator Complex Proteins 0.000 description 1
- 102000000490 Mediator Complex Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 101710166076 Mitogen-activated protein kinase 5 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 1
- 101710202845 Serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses an arylurea compound shown as a formula (I), a preparation method and a pharmaceutical application thereof, a physiologically acceptable salt, a solvate and a crystal form thereof, a preparation method of the compound, a pharmaceutical preparation containing the compound, and clinical application of the compound in treating CDK8 related diseases such as tumors and the like.
Description
Technical Field
The invention relates to the technical field of medicines, and relates to aryl urea compounds with a general formula (I), a preparation method and a medicinal application thereof, and physiologically acceptable salts thereof. The application of the compounds in preparing CDK8 inhibitors and medicaments for treating tumors and medicinal compositions containing the compounds.
Background
Malignant tumors have become serious diseases seriously threatening human health, and the drug therapy plays an important role in the clinical treatment of tumors. The antitumor drugs include cytotoxic drugs and molecular targeted drugs. The nonspecific defect of the former causes damage to normal organs and tissues of tumor patients, and the targeted selectivity of the latter on tumor cells improves the drug effect and reduces the damage to normal organisms. At present, many pharmaceutical companies successfully develop molecular targeted antitumor drugs, and the clinical application of tumor molecular targeted therapy is greatly promoted.
Cyclin-dependent kinases (CDKs) are serine/threonine kinases that are activated upon binding to cyclins (cyclins) and catalyze phosphorylation of substrates. Meanwhile, CDKs regulate cell cycle progression under the synergy of cyclin-dependent kinase inhibitors and play a key role in gene transcription, and are considered as potential therapeutic targets for a variety of diseases including tumors. The successful marketing of these drugs, from pan-CDK inhibitors (Alvocidib) to more specific CDK inhibitors (CDK 4/6 selective inhibitors Palbociclib, ribociclib and Abemaciclib) for decades, validated CDK as a therapeutic target for cancer and demonstrated the importance of achieving subtype-selective inhibition in achieving CDK4/6 selective inhibitors.
CDK8 is a unique member of the CDK family. As one of the key components of the mediator complex, it is involved in multiple signaling pathways, regulating the transcription of the relevant genes under specific circumstances in the organism. CDK8 is highly expressed in many cancer samples and is considered as a potential target for treating malignant tumors such as colorectal cancer, breast cancer, gastric cancer, ovarian cancer, melanoma and the like, and selective inhibition of CDK8 is a feasible way for treating cancers.
To date, various structural types of CDK8 small molecule inhibitors have been reported in the literature, but no CDK8 inhibitors have been successfully marketed due to their pharmacokinetic properties and kinase selectivity. Currently, the development of CDK8 inhibitors is still in the primary stage, with only two CDK8 selective inhibitors (BCD-115 and SEL 120-34A) entering the clinical trial stage. Therefore, the inventors of the present application are intended to provide novel potent selective CDK8 small molecule inhibitors, providing a chemical template for the study of novel anti-tumor drug candidates.
Disclosure of Invention
The invention aims to provide an aryl urea compound shown as a general formula (I).
Another object of the present invention is to provide a process for preparing an arylurea compound represented by the general formula (I) or an analog thereof.
The invention also aims to provide application of the compound shown in the general formula (I) in preparing CDK8 inhibitors and in preparing medicaments for treating tumors.
In order to achieve the purpose of the invention, the invention adopts the following technical scheme:
wherein,
R 1 selected from halogen, trifluoromethyl, single or multiple on benzene ringR 1 A substituent group;
x and Y are selected from N or C;
R 2 selected from H, CF 3 ﹑F﹑CN﹑NO 2 ﹑NH 2 ﹑N(CH 3 ) 2 C1-C3 alkyl, C1-C3 alkoxy or the following fragments:
in another aspect of the present invention, there is provided a compound represented by the general formula (IA):
wherein,
R 1 selected from halogen, trifluoromethyl, having one or more R on the phenyl ring 1 A substituent group;
R 2 is selected from R 2 Selected from H, CF 3 ﹑F﹑CN﹑NO 2 ﹑NH 2 ﹑N(CH 3 ) 2 C1-C3 alkyl, C1-C3 alkoxy or the following fragments:
still another embodiment of the present invention is to provide a compound represented by the general formula (IB):
wherein,
R 1 selected from halogen, trifluoromethyl, having one or more R on the phenyl ring 1 A substituent group;
x and Y are selected from N or C;
another embodiment of the present invention provides the compound or a physiologically acceptable salt thereof, wherein the compound is selected from the group consisting of:
still another embodiment of the present invention provides a method for synthesizing a compound represented by the general formula (I), comprising the steps of:
reacting a compound of formula II with a compound of formula III to produce a compound of formula (I):
wherein R is 1 、R 2 X and Y are as defined above.
The compounds TM-1 to TM-9 were synthesized analogously, for example with compound TM-1, by the following procedure:
taking the compound TM-14 as an example, the compounds TM-10, TM-14 and TM-15 are synthesized similarly through the compounds TM-12 and TM-13, taking the compound TM-14 as an example, and the preparation process is as follows:
the synthesis of compounds TM-16 to TM-25 is similar, taking compound TM-16 as an example, and the preparation process is as follows:
for the preparation of medicaments, the compounds of the general formula (I) are mixed in a known manner with suitable pharmaceutical carrier substances, fragrances, flavors and colors in a known manner and are tableted or coated, or are suspended or dissolved in water or oil with other additional substances.
The invention also relates to a pharmaceutical composition containing a pharmaceutically effective dose of the compound shown in the general formula I and a pharmaceutically acceptable carrier.
The compounds of the invention may be administered orally or parenterally. The oral preparation can be tablet, capsule, and coating agent, and the parenteral preparation can be injection and suppository. These formulations are prepared according to methods well known to those skilled in the art. Adjuvants used for the manufacture of tablets, capsules, coatings are the customary auxiliaries, such as starch, gelatin, gum arabic, silica, polyethylene glycol, solvents for liquid dosage forms, such as water, ethanol, propylene glycol, vegetable oils, such as corn oil, peanut oil, olive oil, etc. The formulations containing the compounds of the present invention may also contain other adjuvants such as surfactants, lubricants, disintegrants, preservatives, flavoring agents, coloring agents, and the like.
The invention also provides application of the compound in preparing CDK8 inhibitors and medicines for treating tumors.
The beneficial technical effects are as follows:
poor specificity of action is one of the major challenges facing current kinase inhibitor research. The compound has the characteristics and advantages of specifically inhibiting CDK8, and is expected to provide a novel, safe and effective CDK8 inhibitor as a small-molecule antitumor drug.
Drawings
FIG. 1. Inhibitory Effect of Compound TM-8 on 25 kinases
Detailed Description
The present invention will be further described with reference to the following examples, which are not intended to limit the scope of the present invention.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) or Mass Spectrometry (MS) or High Resolution Mass Spectrometry (HRMS). The NMR shift (δ) is given in units of parts per million (ppm). m.p. is the melting point given in ° c, the temperature is uncorrected. The column chromatography generally uses 200-300 mesh silica gel as a carrier. NMR was measured using INOVA-300 and CDCl as the solvent 3 、DMSO-D 6 Internal standard is TMS and chemical shifts are given in ppm. MS was measured using an Agilent LC/MSD TOF LC/MS spectrometer.
Example 1: preparation of TM-1
3, 4-dichlorobenzene (188mg, 1.0 mmol) was dissolved in 10mL dichloromethane, 4-fluorophenethylamine (139mg, 1.0 mmol) was added, and the reaction was stirred at room temperature for 2h. After the reaction is finished, a large amount of white solid is generated, the solid is filtered by suction and washed by dichloromethane for several times, and the white solid product is obtained with the yield of about 85 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.80(s,1H),7.84(d,J=2.4Hz,1H),7.44(d,J=8.8Hz,1H),7.28(d,J=5.6Hz,1H),7.25(d,J=5.6Hz,1H),7.22(dd,J=8.8,2.4Hz,1H),7.12(d,J=8.8Hz,2H),6.25(t,J=5.6Hz,1H),3.32(td,J=7.2,5.6Hz,2H),2.68(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δF-C(163.75,161.66,159.74,157.54),154.62,140.61,135.44,135.42,130.75,130.36,130.29,121.96,118.44,117.50,2×F-C-CH(115.00,114.83),40.52,34.64.HR-ESI-MS:m/z=327.04626[M+H] + ,calcd for C 15 H 14 ON 2 Cl 2 F:327.04617.
Example 2: preparation of TM-2
4-methyl phenethylamine and 3, 4-dichlorobenzene isocyanateThus, the synthesis and operation were the same as for compound 1, with a yield of about 78%. 1 H NMR(400MHz,DMSO-d 6 )δ8.80(s,1H),7.84(d,J=2.8Hz,1H),7.43(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.8Hz,1H),7.11(s,4H),6.22(t,J=5.6Hz,1H),3.31(td,J=7.2,5.6Hz,2H),2.70(t,J=7.2Hz,2H),2.27(s,3H); 13 C NMR(125MHz,DMSO-d 6 )δ154.75,140.79,136.29,135.04,130.90,130.43,128.98,128.98,128.56,128.56,122.09,118.57,117.62,40.74,35.27,20.67.HR-ESI-MS:m/z=323.07166[M+H] + ,calcd for C 16 H 17 ON 2 Cl 2 :323.07125.
Example 3: preparation of TM-3
4-nitrophenylethylamine and 3, 4-dichlorobenzene isocyanate, and the synthesis method and operation are the same as those of the compound 1, and the yield is about 62%. 1 H NMR(400MHz,DMSO-d 6 )δ8.81(s,1H),8.18(dd,J=6.8,2.0Hz,2H),7.83(d,J=2.8Hz,1H),7.53(dd,J=6.8,2.0Hz,2H),7.44(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.8Hz,1H),6.33(t,J=5.6Hz,1H),3.40(td,J=7.2,5.6Hz,2H),2.91(t,J=7.2Hz,2H); 13 C NMR(125MHz,DMSO-d 6 )δ154.65,147.89,145.95,140.56,130.76,130.29,129.96,129.96,123.33,123.33,122.06,118.52,117.57,39.94,35.36.HR-ESI-MS:m/z=354.03989[M+H] + ,calcd for C 15 H 14 O 3 N 3 Cl 2 :354.04067.
Example 4: preparation of TM-4
4-nitrophenylethylamine and 4-chloro-3-trifluoromethylphenyl isocyanate, and the synthesis method and operation thereof are the same as those of the compound 1, and the yield is about 61%. 1 H NMR(400MHz,DMSO-d 6 )δ9.00(s,1H),8.18(d,J=8.4Hz,2H),8.05(s,1H),7.54(s,2H),7.53(d,J=8.4Hz,2H),6.38(t,J=5.6Hz,1H),3.40(td,J=6.8,5.6Hz,2H),2.92(t,J=6.8Hz,2H). 13 C NMR(125MHz,DMSO-d6)δ154.84,148.03,146.10,140.09,131.87,130.13,130.13,C-CF 3 (126.93,126.69,126.45,126.21),CF 3 (126.14,123.97,121.80,119.63),123.48,123.48,122.30,121.36,CH-C-CF 3 (116.18,116.13,116.09,116.04),40.12,35.49.HR-ESI-MS:m/z=388.06488[M+H] + ,calcd for C 16 H 14 O 3 N 3 ClF 3 :388.06703.
Example 5: preparation of TM-5
4-trifluoromethyl phenethylamine and 3, 4-dichlorobenzene isocyanate, and the synthesis method and operation are the same as those of the compound 1, and the yield is about 37 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.80(s,1H),7.84(d,J=2.4Hz,1H),7.67(d,J=8.0Hz,2H),7.47(d,J=8.0Hz,2H),7.44(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.4Hz,1H),6.29(t,J=5.6Hz,1H),3.38(td,J=6.8,5.6Hz,2H),2.85(t,J=6.8Hz,2H); 13 C NMR(125MHz,DMSO-d6)δ154.64,144.39,140.58,130.76,130.29,129.45,129.45,CF 3 (127.57,125.40,123.24,121.08),C-CF 3 (127.14,126.89,126.64,126.39),2×CH-C-CF 3 (125.09,125.07,125.03,125.00),122.02,118.49,117.54,40.10,35.28.HR-ESI-MS:m/z=377.04297[M+H] + ,calcd for C 16 H 14 ON 2 Cl 2 F 3 :377.04298.
Example 6: preparation of TM-6
4-trifluoromethyl phenethylamine and 4-chloro-3-trifluoromethyl phenylisocyanate, and the synthesis method and operation are the same as those of the compound 1, and the yield is about 93 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.99(s,1H),8.05(d,J=1.6Hz,1H),7.67(d,J=8.0Hz,2H),7.54(d,J=2.0Hz,1H),7.53(s,1H),7.47(d,J=8.0Hz,2H),6.35(t,J=5.6Hz,1H),3.39(td,J=7.2,5.6Hz,2H),2.86(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ154.68,144.37,139.95,131.71,129.47,129.47,CF 3 (127.56,125.40,123.24,121.08),C-CF 3 (126.89,126.63),C-CF 3 (126.54,126.30),CF 3 (125.96,123.82,121.65,119.48),2×CH-C-CF 3 (125.09,125.06,125.03,125.00),122.13,121.19,CH-C-CF 3 (115.99,115.95,115.91,115.87),40.13,35.28.HR-ESI-MS:m/z=411.07083[M+H] + ,calcd for C 17 H 14 ON 2 ClF 6 :411.06934.
Example 7: preparation of TM-7
4-methoxy phenethylamine and 3, 4-dichlorobenzene isocyanate, and the synthesis method and operation are the same as the compound 1, and the yield is about 84 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.81(s,1H),7.84(d,J=2.4Hz,1H),7.44(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.4Hz,1H),7.13(dd,J=9.6,5.2Hz,1H),7.15(d,J=8.8Hz,1H),6.87(dd,J=9.6,5.2Hz,1H),6.87(d,J=8.8Hz,1H),6.22(t,J=5.6Hz,1H),3.72(s,3H),3.29(td,J=7.2,5.6Hz,2H),2.68(t,J=7.2Hz,2H); 13 C NMR(125MHz,DMSO-d 6 )δ157.54,154.60,140.65,131.08,130.75,130.29,129.49,129.49,121.92,118.40,117.47,113.66,113.66,54.85,40.75,34.65.HR-ESI-MS:m/z=339.06723[M+H] + ,calcd for C 16 H 17 O 2 N 2 Cl 2 :339.06616.
Example 8: preparation of TM-8
4-methoxy phenethylamine and 4-chloro-3-trifluoromethyl phenylisocyanate, and the synthesis method and operation thereof are the same as those of the compound 1, and the yield is about 89%. 1 H NMR(400MHz,DMSO-d 6 )δ8.99(s,1H),8.06(d,J=2.4Hz,1H),7.55(d,J=2.0Hz,1H),7.54(s,1H),7.15(dd,J=6.8,2.0Hz,2H),6.87(dd,J=6.8,2.0Hz,2H),6.27(t,J=5.6Hz,1H),3.72(s,3H),3.29(td,J=7.2,5.6Hz,2H),2.69(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ157.56,154.66,140.03,131.72,131.08,129.51,129.51,C-CF 3 (126.79,126.55,126.31,126.07),CF 3 (126.01,123.84,121.67,119.41),122.07,121.10,CH-C-CF 3 (115.93,115.89,115.85,115.80),113.67,113.67,54.85,40.79,34.66.HR-ESI-MS:m/z=373.09372[M+H] + ,calcd for C 17 H 17 O 2 N 2 ClF 3 :373.09252.
Example 9: preparation of TM-9
The p-3- (2-aminoethyl) pyridine is obtained by reacting 3, 4-dichlorobenzene isocyanate, and the synthesis method and operation are the same as those of the compound 1, and the yield is about 74 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.81(s,1H),8.45(d,J=2.4Hz,1H),8.43(dd,J=4.8,1.6Hz,1H),7.83(d,J=2.4Hz,1H),7.66(dt,J=8.0,1.6Hz,1H),7.44(d,J=8.8Hz,1H),7.35-7.31(m,1H),7.22(dd,J=8.8,2.4Hz,1H),6.31(t,J=5.6Hz,1H),3.36(q,J=6.8,5.6Hz,2H),2.78(t,J=6.8Hz,2H); 13 C NMR(125MHz,DMSO-d 6 )δ154.63,149.79,147.33,140.59,136.11,134.79,130.75,130.29,123.37,122.01,118.48,117.54,40.08,32.58.HR-ESI-MS:m/z=310.05148[M+H] + ,calcd for C 14 H 14 ON 3 Cl 2 :310.05084.
Example 10: preparation of TM-10
1) 1- (3, 4-dichlorophenyl) -3- (4-hydroxyphenylethyl) urea
3, 4-dichlorobenzene (188mg, 1.0 mmol) was dissolved in 10mL of dichloromethane, p-hydroxyphenylethylamine (137mg, 1.0 mmol) was added, and the reaction was stirred at room temperature for 2 hours. After the reaction was completed, a large amount of white solid was produced, and the solid was filtered with suction and washed with dichloromethane several times to obtain the product as a white solid (210 mg, yield 65%).
2) 1- (3, 4-dichlorophenyl) -3- (4- (2-morpholin-2-oxyethoxy) phenethyl) urea
1- (3, 4-dichlorophenyl) -3- (4-hydroxyphenylethyl) urea (324mg, 1.0mmol), 4- (2-chloroacetyl) morpholine (163mg, 1.0mmol) and K were weighed 2 CO 3 (276 mg,2.0 mmol), KI (84mg, 0.5 mmol), dissolved in 10mL DMF and stirred at 80 deg.C in an oil bath for about 6h. After the reaction is finished, the DMF is evaporated to dryness under reduced pressure, anhydrous ether is added, and a white solid product is separated out by stirring, wherein the yield is about 82%. 1 H NMR(400MHz,DMSO-d 6 )δ8.89(s,1H),7.85(d,J=2.0Hz,1H),7.44(d,J=6.8Hz,1H),7.22(dd,J=6.8,2.0Hz,1H),7.14(d,J=6.8Hz,2H),6.86(d,J=6.8Hz,2H),6.31(t,J=4.4Hz,1H),4.79(s,2H),3.62-3.54(m,4H),3.47-3.43(m,4H),3.28(dd,J=5.6,4.4Hz,2H),2.68(t,J=5.6Hz,2H); 13 C NMR(125MHz,DMSO-d 6 )δ165.99,156.32,154.64,140.68,131.56,130.75,130.28,129.38,129.38,121.90,118.40,117.47,114.38,114.38,65.95,65.90,65.65,44.62,41.44,40.72,34.64.HR-ESI-MS:m/z=452.11447[M+H] + ,calcd for C 21 H 24 O 4 N 3 Cl 2 :452.11384.
Example 11: preparation of TM-11
1- (4-chloro-3- (trifluoromethyl) phenyl) -3- (4-hydroxyphenylethyl) urea and 2-chloro-1-morpholinoethan-1-one, and synthetic method, operation and combination thereofThe yield was about 65% with the same thing 10. 1 H NMR(400MHz,DMSO-d 6 )δ9.02(s,1H),8.07(d,J=2.4Hz,1H),7.57-7.51(m,2H),7.14(d,J=8.6Hz,2H),6.86(d,J=8.6Hz,2H),6.31(t,J=5.6Hz,1H),4.78(s,2H),3.63–3.53(m,4H),3.48-3.42(m,4H),3.31(td,J=7.2,5.6Hz,2H),2.69(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ166.00,156.33,154.68,140.05,131.72,131.55,129.40,129.40,C-CF 3 (26.79,126.55,126.31,126.06),CF 3 (126.01,123.84,121.67,119.50),122.08,121.10,CH-C-CF 3 (115.89,115.84),114.39,114.39,65.95,65.91,65.66,44.63,41.45,40.77,34.65.HR-ESI-MS:m/z=486.14102[M+H] + ,calcd for C 22 H 24 O 4 N 3 ClF 3 :486.14020.
Example 12: preparation of TM-12
The compound is obtained by weighing 1- (3, 4-dichlorophenyl) -3- (4-hydroxyphenylethyl) urea and ethyl bromoacetate for reaction, and the synthesis method and operation thereof are the same as the compound 10, and the yield is about 68 percent. 1 H NMR(400MHz,DMSO-d 6 )δ8.80(s,1H),7.85(d,J=2.4Hz,1H),7.43(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.4Hz,1H),7.15(dd,J=6.8,2.0Hz,2H),6.86(dd,J=6.8,2.0Hz,2H),6.25(t,J=5.6Hz,1H),4.74(s,2H),4.16(q,J=7.2Hz,2H),3.29(td,J=7.8,5.6Hz,2H),2.68(t,J=7.8Hz,2H),1.21(t,J=7.2Hz,3H); 13 C NMR(125MHz,DMSO-d 6 )δ168.72,155.92,154.6,140.64,131.89,130.75,130.29,129.51,129.51,121.93,118.41,117.48,114.27,114.27,64.48,60.47,40.67,34.61,13.94.HR-ESI-MS:m/z=411.08682[M+H] + ,calcd for C 19 H 21 O 4 N 2 Cl 2 :411.08729.
Example 13: preparation of TM-13
Dissolving compound 2- (4- (2- (3- (3- (3, 4-dichlorophenyl) ureido) ethyl) phenoxy) ethyl acetate (410mg, 1.0 mmol) in 20ml of absolute ethyl alcohol, dropwise adding 4ml of 1M NaOH aqueous solution, stirring at room temperature for 2h, after the reaction is finished, evaporating the solvent under reduced pressure, adding distilled water for dissolving, washing with ethyl acetate, adjusting the pH of an aqueous layer to about 5 by using 1M HCl aqueous solution, and precipitating white solid with the yield of about 72%. 1 H NMR(400MHz,DMSO-d 6 )δ10.46(s,1H),7.88(d,J=2.0Hz,1H),7.75(t,J=5.2Hz,1H),7.37(d,J=9.2Hz,1H),7.32(dd,J=9.2,2.0Hz,1H),7.07(dd,J=7.2,1.2Hz,2H),6.75(dd,J=7.2,1.2Hz,2H),4.18(s,2H),3.19(td,J=6.8,5.2Hz,2H),2.58(t,J=6.8Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ172.07,157.12,155.32,141.66,130.67,130.50,130.03,129.14,129.14,120.99,118.08,117.30,114.12,114.12,67.42,40.85,34.44.HR-ESI-MS:m/z=383.05566[M+H] + ,calcd for C 17 H 17 O 4 N 2 Cl 2 :383.05599.
Example 14: preparation of TM-14
2- (4- (2- (3, 4-dichlorophenyl) ureido) ethyl) phenoxy) acetic acid (191mg, 0.5 mmol), 4-aminopyridine (56.5 mg,0.6 mmol), HATU (228mg, 0.6 mmol), DIEA (129mg, 1.0 mmol) were weighed out and dissolved in 10mL of a mixed solvent of dichloromethane and DMF (1: 1), and the reaction was stirred at room temperature for about 4 hours. After the reaction is finished, the solvent is evaporated to dryness under reduced pressure, ethyl acetate is added, the mixture is washed by saturated saline solution, the organic layer is concentrated to obtain a crude product, and the crude product is subjected to silica gel column chromatography to obtain a white solid product with the yield of about 67%. 1 H NMR(400MHz,DMSO-d 6 )δ10.46(s,1H),8.85(s,1H),8.44(dd,J=4.4,1.6Hz,2H),7.84(d,J=2.4Hz,1H),7.62(dd,J=4.4,1.6Hz,2H),7.43(d,J=8.8Hz,1H),7.22(dd,J=8.8,2.4Hz,1H),7.17(dd,J=6.8,2.0Hz,2H),6.93(dd,J=6.8,2.0Hz,2H),6.29(t,J=5.6Hz,1H),4.72(s,2H),3.29(td,J=6.8,5.6Hz,2H),2.69(t,J=6.8Hz,2H); 13 C NMR(125MHz,DMSO-d 6 )δ167.88,156.03,154.62,150.30,150.30,144.95,140.66,132.01,130.73,130.27,129.55,129.55,121.89,118.40,117.47,114.43,114.43,113.38,113.38,66.91,40.68,34.64;HR-ESI-MS:m/z=459.09915[M+H] + ,calcd for C 22 H 21 O 3 N 4 Cl 2 :459.09852.
Example 15: preparation of TM-15
2- (4- (2- (3- (4-chloro-3- (trifluoromethyl) phenyl) ureido) ethyl) phenoxy) acetic acid and 4-aminopyridine, the synthesis and operation of which are the same as those of compound 14, with a yield of about 77%. 1 H NMR(400MHz,DMSO-d 6 )δ10.95(s,1H),8.99(s,1H),8.59(dd,J=5.6,1.6Hz 2H),8.06(d,J=2.0Hz,1H),7.87(dd,J=5.6,1.6Hz 2H),7.54(d,J=2.0Hz,1H),7.54(s,1H),7.18(dd,J=6.4,2.0Hz 2H),6.94(dd,J=6.4,2.0Hz 2H),6.30(t,J=5.6Hz,1H),4.79(s,2H),3.31(td,J=7.2,5.6Hz,2H),2.70(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ168.81,156.11,154.83,148.77,146.63,140.17,132.28,131.88,129.75,129.75,C-CF 3 (126.94,126.70,126.46,126.22),CF 3 (126.16,123.99,121.82,119.80),122.25,121.29,2×CH-C-CF 3 (116.06,116.04,116.02,115.97)114.62,114.62,114.13,114.13,67.10,40.91,34.82.HR-ESI-MS:m/z=493.12518[M+H] + ,calcd for C 23 H 21 O 3 N 4 ClF 3 :493.12488.
Example 16: preparation of TM-16
1) Tert-butyl (4-nitrophenylethyl) carbamate
4-Nitrobenzene ethylamine hydrochloride (202mg, 1.0 mmol) was dissolved in 10mL of dichloromethane, and Boc anhydride (218mg, 1.0 mmol) and DMAP (122mg, 1.0 mmol) were added to stir the reaction at room temperature for 5 hours. After the reaction is finished, washing with saturated NaCl, evaporating the organic layer under reduced pressure to dryness to obtain a light yellow product, adding distilled water, stirring, and performing suction filtration to obtain a white solid with the yield of about 92%.
2) Tert-butyl (4-aminophenylethyl) carbamate
The compound tert-butyl (4-nitrophenylethyl) carbamate (266mg, 1.0 mmol) was dissolved in 5ml of methanol, pd/C (80mg, 10%) was added, and after 5 replacements with a hydrogen balloon, protection was continued and stirring was carried out at room temperature for 2 hours. After the reaction, pd/C was removed with celite, and after washing with methanol several times, the solvent was evaporated to dryness under reduced pressure to give 210mg of a white solid with a yield of about 89%.
3) Tert-butyl (4- (isonicotinamide) phenethyl) carbamate
Tert-butyl (4-aminophenylethyl) carbamate (236mg, 1.0 mmol), isonicotinic acid (123mg, 1.0 mmol), HATU (379mg, 1.0 mmol), DIEA (129mg, 1.0 mmol) were weighed out, dissolved in 10mL of a mixed solvent of dichloromethane and DMF (1: 1), and the reaction was stirred at room temperature for about 4 hours. After the reaction is finished, the solvent is evaporated to dryness under reduced pressure, ethyl acetate is added, the mixture is washed by saturated saline solution, an organic layer is concentrated to obtain a crude product, and the crude product is subjected to silica gel column chromatography to obtain a white solid product with the yield of about 65%.
4) N- (4- (2-aminoethyl) phenyl) isonicotinamide
Tert-butyl (4- (isonicotinamide) phenethyl) carbamate (130mg, 0.3mmol) was dissolved in 2mL of dichloromethane, 2.0mL of trifluoroacetic acid was added, and the reaction was stirred at room temperature for 2h. After the reaction, the residual solvent was distilled off, a saturated aqueous solution of sodium carbonate was added to the reaction system, the system was extracted with ethyl acetate, and the organic layers were combined and concentrated to give a light brown oil with a yield of about 89.2%.
5) N- (4- (2- (3, 4-dichlorophenyl) ureido) ethyl) phenyl) isonicotinamide
The N- (4- (2-aminoethyl) phenyl) isonicotinamide is obtained by reacting 3, 4-dichlorobenzene isocyanate with the same synthetic method and operation as compound 1, and the yield is about 54%. 1 H NMR(400MHz,DMSO-d 6 )δ10.45(s,1H),8.83(s,1H),8.78(dd,J=4.4,1.8Hz,2H),7.85(dd,J=4.4,1.8Hz,2H),7.84(s,1H),7.70(dd,J=6.4,1.6Hz,2H),7.44(d,J=8.8Hz,1H),7.24(dd,J=6.4,1.6Hz,2H),7.22(dd,J=8.8,2.8Hz,1H),6.27(t,J=5.6Hz,1H),3.35(td,J=7.2,5.6Hz,2H),2.73(d,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ163.68,154.62,150.14,150.14,141.83,140.64,136.61,135.15,130.75,130.29,128.79,128.79,121.94,121.44,121.44,120.41,120.41,118.43,117.49,40.52,35.02.HR-ESI-MS:m/z=429.08813[M+H] + ,calcd for C 21 H 19 O 2 N 4 Cl 2 :429.08796.
Example 17: preparation of TM-17
N- (4- (2-aminoethyl) phenyl) isonicotinamide and 4-chloro-3-trifluoromethylphenyl isocyanate, and the synthesis method and operation are the same as those of compound 16, and the yield is about 52%. 1 H NMR(400MHz,DMSO-d 6 )δ10.45(s,1H),9.02(s,1H),8.78(dd,J=4.4,1.6Hz,2H),8.07(d,J=2.0Hz,1H),7.85(dd,J=4.4,1.6Hz,2H),7.71(dd,J=6.8,2.0Hz,2H),7.55(d,J=2.0Hz,1H),7.54(s,1H),7.25(dd,J=6.8,2.0Hz,2H),6.33(t,J=5.6Hz,1H),3.36(td,J=7.2,5.6Hz,2H),2.75(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ163.68,154.67,150.14,150.14,141.83,140.03,136.62,135.13,131.72,128.79,128.79,C-CF 3 (126.83,126.54,126.30,126.00),CF 3 (125.86,123.83,121.66,119.45),122.08,121.44,121.44,120.40,120.40,2×CH-C-CF 3 (115.93,115.90,115.85,115.81),40.57,35.03.HR-ESI-MS:m/z=463.11450[M+H] + ,calcd for C 22 H 19 O 2 N 4 ClF 3 :463.11431.
Example 18: preparation of TM-18
N- (4- (2-aminoethyl) phenyl) -2-morpholinecarboxamide is reacted with 3, 4-dichlorobenzene isocyanate in the same manner and operation as compound 16, with a yield of about 44%. 1 H NMR(400MHz,DMSO-d 6 )δ9.66(s,1H),8.81(s,1H),7.84(d,J=2.4Hz,1H),7.55(dd,J=6.4,2.0Hz,2H),7.43(d,J=8.8Hz,1H),7.21(dd,J=8.8,2.4Hz,1H),7.16(dd,J=6.4,2.0Hz,2H),6.23(t,J=5.6Hz,1H),3.66-3.60(m,4H),3.29(td,J=7.2,5.6Hz,2H),3.10(s,2H),2.70(t,J=7.2Hz,2H),2.51-2.48(m,4H). 13 C NMR(125MHz,DMSO-d 6 )δ167.72,154.60,140.63,136.61,134.25,130.74,130.29,128.70,128.70,121.93,119.45,119.45,118.41,117.47,65.94,65.94,61.92,53.04,53.04,40.57,34.97.HR-ESI-MS:m/z=451.13205[M+H] + ,calcd for C 21 H 25 O 3 N 4 Cl 2 :451.12982.
Example 19: preparation of TM-19
N- (4- (2-aminoethyl) phenyl) -2-morpholinecarboxamide is reacted with 4-chloro-3-trifluoromethylphenyl isocyanate, the synthesis and operation are the same as those of compound 16, and the yield is about 40%. 1 H NMR(400MHz,DMSO-d 6 )δ9.66(s,1H),8.99(s,1H),8.06(d,J=2.0Hz,1H),7.56(dd,J=6.4,2.0Hz,2H),7.54(s,2H),7.17(dd,J=6.4,2.0Hz,2H),6.28(t,J=5.6Hz,1H),3.66-3.61(m,4H),3.30(td,J=7.2,5.6Hz,2H),3.10(s,2H),2.70(t,J=7.2Hz,2H),2.51-2.48(m,4H). 13 C NMR(125MHz,DMSO-d 6 )δ167.74,154.65,140.01,136.62,134.25,131.72,128.72,128.72,C-CF 3 (126.78,126.54,126.30,126.05),CF 3 (126.00,123.83,121.66,119.16),122.08,121.11,119.46,119.46,CH-C-CF 3 (115.90,115.85),65.95,65.95,61.93,53.05,53.05,40.61,34.97.HR-ESI-MS:m/z=485.15747[M+H] + ,calcd for C 22 H 25 O 3 N 4 ClF 3 :485.15618.
Example 20: preparation of TM-20
N- (4- (2-aminoethyl) phenyl) -5-chloro-1H-indole-2-carboxamide is reacted with 3, 4-dichlorophenylisocyanate in the same manner and in the same operation as compound 16 in about 75% yield. 1 H NMR(400MHz,DMSO-d 6 )δ11.94(s,1H),10.25(s,1H),8.83(s,1H),7.85(d,J=2.0Hz,1H),7.77(d,J=2.8Hz,1H),7.72(dd,J=6.4,2.0Hz,2H),7.47(d,J=8.8Hz,1H),7.44(d,J=8.8Hz,1H),7.40(d,J=1.6Hz,1H),7.25-7.21(m,4H),6.26(t,J=5.6Hz,1H),3.34(td,J=7.2,5.6Hz,2H),2.74(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ159.10,154.63,140.65,136.82,135.01,134.60,132.89,130.76,130.30,128.80,128.80,127.92,124.23,123.70,121.95,120.65,120.15,120.15,118.43,117.49,113.85,103.12,40.54,35.02.HR-ESI-MS:m/z=501.06482[M+H] + ,calcd for C 24 H 20 O 2 N 4 Cl 3 :501.06464.
Example 21: preparation of TM-21
The N- (4- (2-aminoethyl) phenyl) -5-chloro-1H-indole-2-carboxamide is obtained by reacting 4-chloro-3-trifluoromethylphenyl isocyanate, and the synthesis method and operation are the same as those of the compound 16, and the yield is about 43%. 1 H NMR(400MHz,DMSO-d 6 )δ11.93(d,J=2.0Hz,1H),10.25(s,1H),9.00(s,1H),8.07(d,J=2.4Hz,1H),7.77(d,J=2.0Hz,1H),7.73(dd,J=6.4,2.0Hz,2H),7.55(d,J=2.0Hz,1H),7.54(s,1H),7.48-7.45(td,J=8.8,0.8Hz,1H),7.40(dd,J=2.4,0.8Hz,1H),7.25(dd,J=6.4,2.0Hz,2H),7.22(dd,J=8.8,2.0Hz,1H),6.31(t,J=5.6Hz,1H),3.36(td,J=7.2,5.6Hz,2H),2.75(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ159.10,154.67,140.01,136.82,135.01,134.58,132.88,131.72,128.80,128.80,127.92,C-CF 3 (126.80,126.54,126.30,126.07),CF 3 (125.88,123.83,121.66,119.40),124.23,123.70,122.09,121.13,120.65,120.15,2×CH-C-CF 3 (115.91,115.86),113.85,103.12,40.58,35.01.HR-ESI-MS:m/z=535.09161[M+H] + ,calcd for C 25 H 20 O 2 N 4 Cl 2 F 3 :535.09099.
Example 22: preparation of TM-22
N- (4- (2-aminoethyl) phenyl) -5-methylisoxazole-3-carboxamide is reacted with 3, 4-dichlorobenzene isocyanate in the same synthetic method and operation as compound 16, with a yield of about 33%. 1 H NMR(400MHz,DMSO-d 6 )δ10.57(s,1H),8.82(s,1H),7.84(d,J=2.8Hz,1H),7.71(d,J=6.8,2.0Hz,2H),7.44(d,J=8.8Hz,1H),7.22(d,J=8.8Hz,1H),7.21(dd,J=6.8,2.0Hz,2H),6.65(d,J=0.8Hz,1H),6.25(t,J=5.6Hz,1H),3.34(td,J=7.2,5.6Hz,2H),2.73(t,J=7.2Hz,2H),2.49(s,3H). 13 C NMR(125MHz,DMSO-d 6 )δ171.28,159.14,157.14,154.61,140.64,136.09,135.29,130.75,130.29,128.78,128.78,121.94,120.47,120.47,118.42,117.49,101.51,40.48,34.99,11.77.HR-ESI-MS:m/z=433.08200[M+H] + ,calcd for C 20 H 19 O 3 N 4 Cl 2 :433.08287.
Example 23: preparation of TM-23 (ZHC-3-8)
N- (4- (2-aminoethyl) phenyl) -5-methylisoxazole-3-carboxamide is reacted with 4-chloro-3-trifluoromethylphenylisocyanate in the same manner and in the same operation as compound 16, giving a yield of about 53%. 1 H NMR(400MHz,DMSO-d 6 )δ10.57(s,1H),9.00(s,1H),8.06(d,J=2.0Hz,1H),7.72(dd,J=6.8,1.6Hz,2H),7.54(d,J=2.4Hz,1H),7.54(s,1H),7.22(dd,J=6.8,1.6Hz,2H),6.65(d,J=0.8Hz,1H),6.30(t,J=5.6Hz,1H),3.32(td,J=7.2,5.6Hz,2H),2.74(t,J=7.2Hz,2H),2.49(s,3H). 13 C NMR(125MHz,DMSO-d 6 )δ171.28,159.14,157.14,154.66,140.01,136.10,135.27,131.72,128.78,128.78,C-CF 3 (126.76,126.54,126.30,126.07),CF 3 (126.00,123.83,121.66,119.55),122.08,121.12,120.47,120.47,CH-C-CF 3 (115.91,115.86),101.51,40.52,34.99,11.77.HR-ESI-MS:m/z=467.10919[M+H] + ,calcd for C 21 H 19 O 3 N 4 ClF 3 :467.10923.
Example 24: preparation of TM-24
N- (4- (2-aminoethyl) phenyl) furan-2-carboxamide is reacted with 3, 4-dichlorobenzene isocyanate in the same synthetic method and operation as compound 16, with about 48% yield. 1 H NMR(400MHz,DMSO-d 6 )δ10.12(s,1H),8.82(s,1H),7.93(q,J=0.8Hz,1H),7.85(d,J=2.8Hz,1H),7.68(dd,J=6.8,2.0Hz,2H),7.44(d,J=8.0Hz,1H),7.31(dd,J=3.6,0.8Hz,1H),7.22(dd,J=8.0,2.8Hz,1H),7.20(dd,J=6.8,2.0Hz,2H),6.70(dd,J=3.6,2.0Hz,1H),6.25(t,J=5.6Hz,1H),3.34(td,J=7.2,5.6Hz,2H),2.72(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ156.12,154.79,147.59,145.67,140.81,136.69,134.80,130.92,130.45,128.87,128.87,122.10,120.50,120.50,118.58,117.65,114.63,112.18,40.68,35.15.HR-ESI-MS:m/z=418.07260[M+H] + ,calcd for C 20 H 18 O 3 N 3 Cl 2 :418.07197.
Example 25: preparation of TM-25
N- (4- (2-aminoethyl) phenyl) furan-2-carboxamide with 4-chloro-3-trifluoro-3The methyl phenyl isocyanate is obtained by reaction, the synthesis method and operation are the same as those of the compound 16, and the yield is about 32%. 1 H NMR(400MHz,DMSO-d 6 )δ10.12(s,1H),9.00(s,1H),8.07(d,J=1.6Hz,1H),7.93(d,J=1.2Hz,1H),7.68(d,J=8.4Hz,2H),7.55(d,J=2.4Hz,1H),7.54(s,1H),7.31(d,J=3.2Hz,1H),7.21(d,J=8.4Hz,2H),6.70(q,J=1.6Hz,1H),6.30(t,J=5.6Hz,1H),3.34(td,J=7.2,5.6Hz,2H),2.73(t,J=7.2Hz,2H). 13 C NMR(125MHz,DMSO-d 6 )δ155.97,154.67,147.43,145.51,140.02,136.54,134.63,131.72,128.71,128.71,C-CF 3 (126.79,126.55,126.31,126.06),CF 3 (125.89,123.83,121.66,119.50),122.08,121.12,120.34,120.34,CH-C-CF 3 (115.90,115.86),114.47,112.03,40.56,34.98.HR-ESI-MS:m/z=452.09891[M+H] + ,calcd for C 21 H 18 O 3 N 3 ClF 3 :452.09833.
Pharmacological experiments:
experimental example 1: in vitro kinase inhibition Activity assay
The evaluation of the activity of the compounds on the molecular level of CDK8/cyclin C was entrusted to the company Thermo Fisher Scientific (Sammerfei, USA).
In the experiment, the compounds were diluted 100-fold in DMSO solution, with buffer solution (50mM HEPES pH 7.5,0.01% 2 1mM EGTA), the mixture of kinase and antibody and Tracer were mixed, shaken for 30s, and then incubated at room temperature for 60min. Subsequently, the emulsion Ratio (ER, AF647 emulsion (665 nm) to Europium emulsion (615 nm)) was read on a microplate reader and analyzed. In the IC50 assay, compounds were diluted in 3-fold gradients for a total of 10 concentrations tested. Blank control was set in the test and positive control was sorafenib as reference. The results are given as a percentage of "the difference between the ER of the blank and the ER of the test sample" and "the difference between the ER of the blank and the ER of the positive control", a larger percentage indicating better binding of the compound to the kinase. Table 1is the results of the in vitro inhibitory activity of CDK8 kinase of the compounds of the present invention.
TABLE 1 inhibitory Effect of Compounds on CDK8/cyclin C
ND: not Determined, not tested.
Experimental example 2: in vitro kinase Selective Activity assay
The compound TM-8 with the highest CDK8 inhibitory activity is selected to test the inhibitory activity of the compound TM-8 on other 24 kinases. 5 of them are CDK subtypes, including CDK1, CDK2, CDK6, CDK7 and CDK9; another 19 kinase families involved are the seven classes GSK3A, BRAF, CAMK4, CLK1, CSNK1D, DAPK1, FGFR1, JAK1, LRRK2, MARK1, MAP2K5, MAPK7, p38 α, MKNK1, MST4, PDK1, PKC α, PTK2, and SRC, respectively. The inhibitory effect of selected compound TM-8 of the invention on 25 kinases including CDK8 at a concentration of 10 μ M is shown in table 2 and figure 1.
TABLE 2 inhibitory Effect of Compound TM-8 on 25 kinases
* Each test was repeated twice at a concentration of 10 μ M.
CDK: cyclin dependent kinases (Cyclin dependent kinases); GSK3A: glycogen synthase kinase 3 α (glycogen synthase kinase 3 α); BRAF: sarcoma viral oncogene homolog B1 (v-raf murine sarcococcal oncogene homolog B1); caMK4: calcium/calmodulin-dependent protein kinase 4 (Calcium/calmodulin-dependent protein kinase 4); CLK1: CDC-like kinase 1 (CDC like kinase 1); CSNK1D: tyrosine kinase 1D (Casein kinase 1isoform delta); DAPK1: death-associated protein kinase 1 (Death-associated protein kinase 1); FGFR1: fibroblast Growth Factor Receptor 1 (Fibroblast Growth Factor Receptor-1); JAK1: janus kinase 1 (Janus kinase 1); LRRK2: leucine-rich repeat kinase 2 (Leucine-rich repeat kinase/threonine-protein kinase 2); MARK1: microtubule Affinity modulating Kinase 1 (Microtubule Affinity modulating Kinase 1); MAP2K5: dual specificity mitogen-activated protein kinase kinase5 (Dual specificity mitogen-activated protein kinase 5); MAPK7: mitogen-activated protein kinase 7 (Mitogen-activated protein kinase 7); MAPK14: mitogen-activated protein kinase 14 (Mitogen-activated protein kinase 14); MKNK1: MAP kinase-interacting serine/threonine kinase 1 (MAP kinase-interacting serine/threonine-protein kinase 1); MST4: serine/threonine protein kinase 4 (Mammalian Ste20-like kinase 4); PDK1: 3-phosphoinositide-dependent protein kinase 1 (3-phosphoinositide-dependent protein kinase 1); PRKCA: protein kinase C α (Protein kinase C α); FAK: focal adhesion kinase (Focal adhesion kinase 1); SRC: proto-oncogene tyrosine-protein kinase (proto-oncogene tyrosine-protein kinase).
Experimental example 3: in vitro antitumor cell Activity test (MTT)
Taking tumor cells in logarithmic growth phase, digesting with pancreatin to prepare cell suspension, and inoculating the cell suspension into a 96-well plate according to the number of the cells of about 1500/well, wherein each well is 100 mu L. When tumor cells grow, fresh culture medium of test compounds and corresponding solvent control at different concentrations is added the next day, 100 μ L (DMSO final concentration < 0.1%) is added to each well, and the compound is initially screened to set three doses (0.1 μ M,1 μ M,10 μ M), and single-concentration inhibition rate can also be directly tested. After the test compound addition was complete, incubation was continued for 96h in a 37 ℃ incubator, the supernatant discarded and 200. Mu.L of freshly prepared serum-free medium containing 0.5mg/mL MTT was added to each well. Continuously culturing for 4h, removing the supernatant, adding 200 μ L DMSO into each well to dissolve the precipitate, shaking and mixing uniformly by a micro-oscillator, and measuring Optical Density (OD) value under the condition of 570nm wavelength by a microplate reader. The tumor cells treated by the solvent are taken as a control group, and the inhibition rate of the drug on the tumor cells is calculated according to the following formula.
Inhibition (%) = (control mean OD value-test compound mean OD value)/control mean OD value × 100%. Calculating IC by using logarithm of compound concentration and inhibition rate as regression equation 50 The value is obtained. Table 3 shows the results of the in vitro antitumor cell activities (MTT) of the compounds of the present invention.
TABLE 3 in vitro antitumor cell Activity of part of the Compounds
Claims (9)
1. An arylurea compound represented by the following general formula (I) or a physiologically acceptable salt thereof,
wherein,
R 1 selected from halogen, trifluoromethyl, having one or more R on the phenyl ring 1 A substituent group;
x and Y are selected from N or C;
R 2 selected from H, CF 3 ﹑F﹑CN﹑NO 2 ﹑NH 2 ﹑N(CH 3 ) 2 C1-C3 alkyl, C1-C3 alkoxy or the following fragments:
2. the compound of claim 1, wherein the compound is a compound of formula (IA) or a physiologically acceptable salt thereof:
wherein,
R 1 selected from halogen, trifluoromethyl, having one or more R on the phenyl ring 1 A substituent group;
R 2 selected from H, CF 3 ﹑F﹑CN﹑NO 2 ﹑NH 2 ﹑N(CH 3 ) 2 C1-C3 alkyl, C1-C3 alkoxy or the following fragments:
5. a process for the preparation of a compound according to any one of claims 1 to 4, comprising the steps of:
the compounds TM-1 to TM-9 were synthesized analogously, for example with compound TM-1, by the following procedure:
taking compound TM-14 as an example, the synthesis methods of compounds TM-10, TM-14 and TM-15 are similar and are obtained by synthesizing compounds TM-12 and TM-13, taking compound TM-14 as an example, the preparation process is as follows:
the synthesis of compounds TM-16 to TM-25 is similar, taking compound TM-16 as an example, and the preparation process is as follows:
6. a pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 5 or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is selected from the group consisting of tablets, capsules, pills, injections, sustained release formulations, controlled release formulations, and various microparticle delivery systems.
8. Use of a compound according to any one of claims 1 to 5 or a physiologically acceptable salt thereof in the preparation of a CDK8 inhibitor.
9. Use of a compound according to any one of claims 1 to 5 or a physiologically acceptable salt thereof for the manufacture of a medicament for the treatment of tumours.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110441682.XA CN115232030A (en) | 2021-04-23 | 2021-04-23 | Aryl urea compound and preparation method and pharmaceutical application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110441682.XA CN115232030A (en) | 2021-04-23 | 2021-04-23 | Aryl urea compound and preparation method and pharmaceutical application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115232030A true CN115232030A (en) | 2022-10-25 |
Family
ID=83666519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110441682.XA Pending CN115232030A (en) | 2021-04-23 | 2021-04-23 | Aryl urea compound and preparation method and pharmaceutical application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115232030A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440383A (en) * | 2000-04-28 | 2003-09-03 | 三共株式会社 | PPAR gamma modulators |
WO2020002969A1 (en) * | 2018-06-26 | 2020-01-02 | Zhejiang Vimgreen Pharmaceuticals, Ltd | Triazolotriazine derivatives as a2a receptor antagonists |
WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
WO2020264176A1 (en) * | 2019-06-28 | 2020-12-30 | Rti International | Urea derivatives as cb1 allosteric modulators |
-
2021
- 2021-04-23 CN CN202110441682.XA patent/CN115232030A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440383A (en) * | 2000-04-28 | 2003-09-03 | 三共株式会社 | PPAR gamma modulators |
WO2020002969A1 (en) * | 2018-06-26 | 2020-01-02 | Zhejiang Vimgreen Pharmaceuticals, Ltd | Triazolotriazine derivatives as a2a receptor antagonists |
WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
WO2020264176A1 (en) * | 2019-06-28 | 2020-12-30 | Rti International | Urea derivatives as cb1 allosteric modulators |
Non-Patent Citations (1)
Title |
---|
CAS:13795-10-3 ET AL.: "CAS:13795-10-3 et al. REGISTRY,STN", CAS:13795-10-3 ET AL. REGISTRY * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107709320B (en) | Pyrido-nitrogen heterocyclic compound and preparation method and application thereof | |
CN106008511B (en) | Pteridine ketone derivatives and its application as EGFR, BLK, FLT3 inhibitor | |
JP7320823B2 (en) | Use of pteridinone derivatives as EGFR inhibitors | |
JP2015110649A (en) | Hydrochloric acid icotinib, composite, crystallographic form, combined medicine and its application | |
CN113200969B (en) | PI3K alpha selective inhibitor and preparation method and application thereof | |
JP2021533186A (en) | Iminosulfone compounds as bromodomain protein inhibitors, pharmaceutical compositions and their pharmaceutical uses | |
CN114437077A (en) | Compounds useful as kinase inhibitors and uses thereof | |
JP2022532141A (en) | Compounds used as kinase inhibitors and their applications | |
CN109641909A (en) | The mechanism target and its treatment use of rapamycin signal pathway inhibitor | |
CN106866642B (en) | Quinazoline compound containing aryl acylhydrazone structure and application thereof | |
CN112759564B (en) | Diaryl urea compound and its prepn and medicinal use | |
CN115232030A (en) | Aryl urea compound and preparation method and pharmaceutical application thereof | |
CN110724137B (en) | Thiophene derivative and preparation method and application thereof | |
CN111233843B (en) | Gamma-butenolide derivative and preparation method and application thereof | |
CN110283174B (en) | PI3K delta inhibitor and application thereof | |
CN111039941B (en) | Nitrogen-containing heterocyclic compound, preparation method and application thereof | |
CN109438279B (en) | Small molecule compound for overcoming EGFR drug-resistant mutation and preparation method and application thereof | |
TWI535724B (en) | New polymorphic forms of icotinib phosphate and uses thereof | |
KR20210122192A (en) | Compounds of Benzothiazole Derivatives | |
CN108117551B (en) | Substituted (1H-pyrazolo [3,4-b ] pyridine) urea compound and anti-tumor application thereof | |
CN113087709A (en) | Pyrrolopyrimidine derivatives, and preparation method and application thereof | |
CN113354630B (en) | 5,6-dihydrobenzo [ h ] quinazoline compound and application thereof | |
CN114539162B (en) | Substituted aryl urea imino diaryl pyrimidine derivative and preparation method and application thereof | |
CN112225733B (en) | Preparation method of 1,3, 4-thiadiazole pyridine-2-ketone derivative and application of derivative as anti-cancer drug | |
CN110698484B (en) | Pyrazolo [1,5-a ] pyrimidine-containing derivative, pharmaceutical composition and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221025 |